INSIDE Intact Vascular raises funds for trials IBM Watson can manage Big Data Do you have a plan for ICD-10? Where’s the ROI in ICD-10?
JUNE/JULY 2015 Vol. 8 No. 4 VEINTHERAPYNEWS.COM
14 16 19 25
An ACP recognized resource for news and information for and about the phlebology community
ACP, VTN expand cooperative editorial, promotion agreement The American College of Phlebology and Vein Therapy News have extended a cooperative agreement to promote educational and timely editorial information to readers of Vein Therapy News (VTN). ACP has designated that VTN is “a recognized resource for news and information for and about the phlebology community.” In the 2014 agreement, VTN provided a section in each issue called ACP UPDATE. The American College of Phlebology (ACP) provided information to the venous treatment community for the section, and VTN provided advertising space for the ACP in three issues to promote any venous disease community programmatic event considered of interest. The 2015 agreement expands on the success of the 2014 agreement. The ACP UPDATE section will be enlarged to provide bylined counterpoint arguments to an issue of interest. VTN has increased the available space for ACP promotional advertising to a full page in each issue.
Pulmonary embolism intervention Dr. Charles B. Ross, with Dr. Robert Powers observing, is performing a pulmonary embolism intervention recently in lab 6 at the Piedmont Heart Institute. Please see the interview with Dr. Ross on page 22.
ACP, VTN
continued on page 12
FDA recalls Medtronic VenaSeal Closure System Medtronic’s VenaSeal Closure System, manufactured by Covidien LLC in the United States, has been recalled by the U.S. Food and Drug Administration because of a possible sterility breach of the outer packaging (pouch) material, which could compromise the outside surface sterility of the sealed inner tray. No units have been sold in the United States, but 1,661 units have been sold in 14 countries, including Australia, Canada, France, Germany, Hong Kong, Ireland, Italy, Latvia, Netherlands, Norway, Portugal, Switzerland, UAE and the United Kingdom. The U.S. launch was scheduled for midspring.
The FDA says it’s now under a Class II recall, reserved for situations in which “use of, or exposure to, a volative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.” The VenaSeal Closure System is intended for patients with superficial varicose veins of the legs that cause symptoms. The sterile kit is made up of an adhesive, a specially formulated n-butyl-2-cyanoacrylate, and delivery system components that include a catheter, guidewire, dispenser gun, dispenser tips, and syringes.
The device must be used as a system and differs from procedures that use drugs, laser, radio waves or cuts in the skin to close or remove veins. A trained healthcare professional inserts the catheter through the skin into the diseased vein to allow injection of the VenaSeal adhesive, a clear liquid that polymerizes into solid material. The healthcare professional monitors proper placement of the catheter using ultrasound imaging during delivery of the adhesive into the diseased vein to seal it. VENASEAL
continued on page 11
CVC 2015 conference detailed The 5th annual Chicago EndoVascular Conference (CVC 2015), will get underway July 8 and continues through July 10 at the Swissotel Chicago, with the Pedal Artery Access Cadaver Course on July 11. CVC 21015 is a comprehensive arterial and venous endovascular conference. “Once a year, a group of impactful and motivated medical professionals dedicated
to the endovascular treatment of arterial and venous disease gather for the CVC experience,” Course Director Jaafer Golzar, MD, FACC, FSCAI, said. “CVC is a winning formula of worldrenowned faculty, dedicated attendees CVC 2015
continued on page 10
PRSRT STD US POSTAGE PAID SAN ANTONIO, TX PERMIT#244